Propella Therapeutics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis of the knee.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2022-04-07 12:18:512022-04-07 12:18:52Press Release: Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China
Propella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)” at the American Society of Clinical Oncology Genitourinary Symposium on February 17, 2022.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2022-02-15 09:01:592022-02-21 09:47:36Presentation: Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)
Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-12-07 09:43:112022-02-15 09:20:10Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-06-29 15:42:032022-01-04 09:10:09Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Press Release: Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China
/in press releases /by georgePropella Therapeutics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis of the knee.
Presentation: Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)
/in presentations /by georgePropella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats (Abstract #160)” at the American Society of Clinical Oncology Genitourinary Symposium on February 17, 2022.
Presentation: 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022)
/in presentations /by georgePropella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.
Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
/in press releases /by georgePropella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.
Presentation: MedInvest Oncology Conference (December 7-10, 2021)
/in presentations /by georgePropella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
/in press releases /by georgePropella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.